

Docket No.: 38342-178463

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Confirmation No.: 6196

Fernando DONÃTE et al.

Serial No: 10/074,225 Group Art Unit: 1642

Filed: February 14, 2002 Examiner: David J. Blanchard

For: HISTIDINE PROLINE-RICH Customer No.: 30827

GLYCOPROTEIN (HPRG) AS AN

ANTIANGIOGENIC AND ANTI-TUMOR

AGENT

<u>INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97</u>

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicant(s) wish to disclose the following information.

REFERENCES

The Applicant(s) wish to make of record the references listed on the attached PTO/SB/08. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.

CERTIFICATION

The undersigned certifies that

certain items of information contained in this information disclosure statement were cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant(s) hereby request consideration of the attached information.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account No. 50-0911. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

hmuel Livnat

Registration No. 33,949

MCKENNA LONG & ALDRIDGE LLP

1900 K Street, N.W.

Washington, D.C. 20006

Telephone No.: (202) 496-7500

Dated: October 14, 2004

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

Application Number 10/074,225

Filing Date February 14, 2002

First Named Inventor Fernando DONÃTE et al.

Art Unit 1642

Examiner Name David J. Blanchard

Attorney Docket Number 38342-178463

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

2

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	ВА	WO 02/076486	03/10/2002	Innoventus Project AB					
	BB	WO 94/28418	08/12/1994	Baylor College of Medicine					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Inter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	ler Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (b magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, ci and/or country where published.			
	CA	Morgan, et al., <i>Histidine-Rich Glycoprotein</i> , Wiley Encyclopedia of Molecular Medicine; Vol. 3, 2002, pp. 1644-1646		
	СВ	Urnov, et al., <i>Histone Acetyltransferase</i> , Wiley Encyclopedia of Molecular Medicine, Vol. 3, p. 2002, p. 1647	-	
	CC	Simantov, et al., <i>Histidine-rich Glycoprotein Inhibits the Antiangiogenic Effect of Thrombospondin-1</i> , The Journal of Clinical Investigation, January 2001, Vol. 107, No. 1, pp. 45-52		
	CD	Sabbatini, et al., Presence in Human Skeletal Muscle of an AMP Deaminase-associated Protein That Reacts with an Antibody to Human Plasma Histidine-Proline-rich Glycoprotein, The Journal of Histochemistry & Cytochemistry, 1999, Vol. 47, pp. 255-260		
,	CE	Borza et al., Histidine-Proline-rich Glycoprotein as a Plasma pH Sensor, The Journal of Biological Chemistry, Vol. 273, No. 10, March 6, 1998, pp. 5493-5499		
	CF	Borza et al., Acceleration of Plasminogen Activation by Tissue Plasminogen Activator on Surface-bound Histidine-proline-rich Glycoprotein, The Journal of Biological Chemistry, Vol. 272, No. 8, February 28, 1997, pp. 5718-5726		
	CG	Borza et al., Domain Structure and Conformation of Histidine-Proline-Rich Glycoprotein, Biochemistry, 1996, pp. 1925-1934		
	СН	Brown, et al., Histidine-Rich Glycoprotein and Platelet Factor 4 Mask Heparan Sulfate Proteoglycans Recognized by Acidic and Basic Fibroblast Growth Factor, Biochemistry, 33, 1994, pp. 13918-13927		
	CI	Hutchens, et al, Synthetic Metal-Binding Protein Surface Domains for Metal Ion-Dependent Interaction Chromatography I. Analysis of Bound Metal Ions by Matrix-Assisted UV Laser Desorption Time-of-flight Mass Spectrometry, Journal of Chromatography, 1992 - Abstract		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).	² Applicant is to place a check mark here if English language	Translation is attached.
Vaminas	ID at a	

Examiner Date Considered

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

2

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

2

Complete if Known				
Application Number	10/074,225			
Filing Date	February 14, 2002			
First Named Inventor	Fernando DONÂTE et al.			
Art Unit	1642			
Examiner Name	David J. Blanchard			
Attorney Docket Number	38342-178463			

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number. Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	•
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ² .
	CK	Katagiri, et al., Interaction of Heme with a Synthetic Peptide Mimicking the Putative Heme- Binding Site of Histidine-Rich Glycoprotein, Biochemical and Biophysical Research Communications, 1987 - Abstract	
	CL	Kingston, et al., <i>Primary Structure of a Histidine-rich Proteolytic Fragment of Human Ceruloplasmin</i> , The Journal of Biological Chemistry, 1980, Vol. 225, pp. 2878-2885	
	СМ	Anti-histidine-Rich Glyco:Protein Monoclonal Antibody Used in the Determination of Histidine-Rich-Glyco-Proteins in Body Samples, 1980 – Abstract	
	CN	Oh-Ishi, et al., Possible Physiological Role of New Peptide Fragments Released from Bovine High Molecular Weight Kininogen by Plasma Kallikrein, Biochemical Pharmacology, 1977, Vol. 26, pp. 115-120	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP.609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.